Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Foster Aaron E.
 2. Date of Event Requiring Statement (Month/Day/Year)
02/11/2019		 3. Issuer Name and Ticker or Trading Symbol
BELLICUM PHARMACEUTICALS, INC [BLCM]
(Last)
(First)
(Middle)
C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Sr VP, Head of Research
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

HOUSTON, TX 77030		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 3,737
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)   (1) 10/27/2024 Common Stock 23,529 $ 7.47 D  
Stock Option (right to buy)   (2) 02/23/2025 Common Stock 8,000 $ 23.47 D  
Stock Option (right to buy)   (3) 01/03/2026 Common Stock 15,000 $ 19 D  
Stock Option (right to buy)   (4) 05/31/2026 Common Stock 30,000 $ 12.39 D  
Stock Option (right to buy)   (5) 01/02/2027 Common Stock 4,500 $ 13.89 D  
Stock Option (right to buy)   (6) 07/02/2027 Common Stock 10,500 $ 11.7 D  
Stock Option (right to buy)   (7) 01/01/2028 Common Stock 18,000 $ 9.23 D  
Stock Option (right to buy)   (8) 07/01/2028 Common Stock 42,000 $ 7.72 D  
Stock Option (right to buy)   (9) 01/31/2029 Common Stock 50,000 $ 3.35 D  
Restricted Stock Units   (10)   (10) Common Stock 1,250 $ (11) D  
Restricted Stock Units   (12)   (12) Common Stock 7,500 $ (11) D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Foster Aaron E.
C/O BELLICUM PHARMACEUTICALS, INC.
2130 W. HOLCOMBE BLVD., STE. 800
HOUSTON, TX 77030		       Sr VP, Head of Research  

Signatures

/s/ Rosemary Y. Williams, Attorney-in-Fact 02/20/2019
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) 25% of the shares subject to the stock option vest and become exercisable on October 28, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
(2) 25% of the shares subject to the stock option vest and become exercisable on February 24, 2016, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
(3) 25% of the shares subject to the stock option vest and become exercisable on January 4, 2017, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
(4) 25% of the shares subject to the stock option vest and become exercisable on June 1, 2017, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
(5) 25% of the shares subject to the stock option vest and become exercisable on January 3, 2018, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
(6) 25% of the shares subject to the stock option vest and become exercisable on July 3, 2018, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
(7) 25% of the shares subject to the stock option vest and become exercisable on January 2, 2019, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
(8) 25% of the shares subject to the stock option vest and become exercisable on July 2, 2019, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
(9) 25% of the shares subject to the stock option vest and become exercisable on January 1, 2020, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
(10) On January 3, 2017, the reporting person was granted restricted stock units (the "RSUs") for 2,500 shares. The RSUs vest in four annual installments beginning on January 3, 2018.
(11) Each RSU represents a contingent right to receive one share of the Issuer common stock.
(12) On January 2, 2018, the reporting person was granted the RSUs for 10,000 shares. The RSUs vest in four equal annual installments beginning on January 2, 2019.
 
Remarks:
EXHIBIT LIST: EX-24 power of attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.